Suppr超能文献

基于药物代谢组学方法结合体外毒代动力学建模与模拟,鉴定顺铂诱导肾毒性的新型早期生物标志物及西咪替丁的肾保护作用。

Identification of Novel and Early Biomarkers for Cisplatin-induced Nephrotoxicity and the Nephroprotective Role of Cimetidine using a Pharmacometabolomic-based Approach Coupled with In Vitro Toxicodynamic Modeling and Simulation.

作者信息

Mody Hardik, Nair Sreenath, Rump Adrian, Vaidya Tanaya R, Garrett Timothy J, Lesko Lawrence, Ait-Oudhia Sihem

机构信息

Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, FL, USA.

Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

J Pharm Sci. 2024 Jan;113(1):268-277. doi: 10.1016/j.xphs.2023.11.018. Epub 2023 Nov 20.

Abstract

Cisplatin is widely used for the treatment of various types of cancer. However, cisplatin-induced nephrotoxicity (CIN) is frequently observed in patients receiving cisplatin therapy which poses a challenge in its clinical utility. Currently used clinical biomarkers for CIN are not adequate for early detection of nephrotoxicity, hence there is a need to identify potential early biomarkers in predicting CIN. In the current study, a combination of in vitro toxicodynamic (TD) modeling and untargeted global metabolomics approach was used to identify novel potential metabolite biomarkers for early detection of CIN. In addition, we investigated the protective role of cimetidine (CIM), an inhibitor of the organic cation transporter 2 (OCT2), in suppressing CIN. We first characterized the time-course of nephrotoxic effects of cisplatin (CIS) and the protective effects of CIM in a human pseudo-immortalized renal proximal tubule epithelial cell line (RPTEC), SA7K cell line. Secondly, we used a mathematical cell-level, in vitro TD modeling approach to quantitatively characterize the time-course effects of CIS and CIM as single agents and combination in SA7K cells. Based on the experimental and modeling results, we selected relevant concentrations of CIS and CIM for our metabolomics study. With the help of PCA (Principal Component Analysis) and PLS-DA (Projection to Latent Structure - Discriminate Analysis) analyses, we confirmed global metabolome changes for different groups (CIS, CIM, CIS+CIM vs control) in SA7K cells. Based on the criterion of a p-value ≤ 0.05 and a fold change ≥ 2 or ≤ 0.5, we identified 20 top metabolites that were significantly changed during the early phase i.e. within first 12 h of CIS treatment. Finally, pathway analysis was conducted that revealed the key metabolic pathways that were most impacted in CIN.

摘要

顺铂被广泛用于治疗各种类型的癌症。然而,在接受顺铂治疗的患者中经常观察到顺铂诱导的肾毒性(CIN),这对其临床应用构成了挑战。目前用于CIN的临床生物标志物不足以早期检测肾毒性,因此需要鉴定预测CIN的潜在早期生物标志物。在本研究中,采用体外毒代动力学(TD)建模与非靶向全局代谢组学方法相结合,以鉴定用于早期检测CIN的新型潜在代谢物生物标志物。此外,我们研究了有机阳离子转运体2(OCT2)抑制剂西咪替丁(CIM)在抑制CIN中的保护作用。我们首先在人永生化肾近端小管上皮细胞系(RPTEC)SA7K细胞系中表征了顺铂(CIS)的肾毒性作用的时间进程以及CIM的保护作用。其次,我们使用数学细胞水平的体外TD建模方法,定量表征CIS和CIM作为单一药物以及联合用药在SA7K细胞中的时间进程效应。基于实验和建模结果,我们选择了相关浓度的CIS和CIM用于我们的代谢组学研究。借助主成分分析(PCA)和偏最小二乘判别分析(PLS-DA),我们确认了SA7K细胞中不同组(CIS、CIM、CIS + CIM与对照组)的全局代谢组变化。基于p值≤0.05和变化倍数≥2或≤0.5的标准,我们鉴定出20种在早期即CIS治疗的前12小时内显著变化的顶级代谢物。最后,进行了通路分析,揭示了在CIN中受影响最大的关键代谢通路。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验